EUVIMEDObjevte EUVIMED
VergleichsstudieOpen access

Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience

Marco Tagliafierro iD, Rahul Kanade, Darina Kirilina, Fady Soliman, Isao Anzai, Susheel Kodali, Torsten Vahl, Rebecca Hahn, Tamim Nazif, Arnar Geirsson, Hiroo Takayama, Michael Argenziano and 3 more

Catheterization and Cardiovascular Interventions · 2026-08 · 108 (2) · 627-635

DOI: 10.1002/ccd.70693 ↗

At a glance

Vergleichsstudie in Catheterization and Cardiovascular Interventions, published online on 2026-06-12. Written by Marco Tagliafierro and 14 co-authors. Institution: Department of Surgery, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, New York, USA. Major MEDLINE topics: Bioprosthesis, Heart Valve Prosthesis, Aortic Valve, Reoperation. 24 references. The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Bioprosthetic aortic valves require reinterventions once they degenerate. Options include redo‐surgical aortic valve replacement (redoSAVR) and Valve‐in‐Valve transcatheter aortic valve replacement (ViV). Women with valvular disease have historically demonstrated higher procedural risks and worse outcomes compared to men. There is a knowledge gap regarding outcomes of aortic valve reinterventions in women.

Aims

We sought to compare outcomes of ViV versus redoSAVR in women with degenerated bioprosthetic surgical valves.

Methods

Consecutive female patients with prior SAVR undergoing isolated ViV or redoSAVR between 2015 and 2025 were included. Primary endpoints were 30‐day all‐cause mortality, stroke, and major adverse cardiac events (MACE). Secondary (1‐year) endpoints included mortality, stroke, MACE, pacemaker implantation, and cardiac rehospitalization. Propensity score matching (PSM), Cox regression for survival, and Kaplan‐Meier for MACE were performed.

Results

Forty redoSAVR and 92 ViV female patients were included. ViV females were older, had lower BMI, and higher STS‐PROM. Primary endpoints were not significantly different between ViV and redoSAVR: mortality 1 (1.1%) versus 1 (2.5%), p = 0.303; stroke 3 (3.3%) versus 2 (5.0%), p = 0.480; MACE 3 (3.3%) versus 3 (7.5%), p = 0.272. 1‐year endpoints were also comparable: mortality 8 (8.7%) versus 3 (7.5%), p = 0.867; stroke 4 (4.3%) versus 2 (5.0%), p = 0.834; MACE 11 (12.0%) versus 5 (12.5%), p = 0.888; pacemaker 3 (3.3%) versus 1 (2.5%), p = 0.792; rehospitalization 10 (10.9%) versus 2 (5.0%), p = 0.265). Results were consistent before and after PSM.

Conclusions

ViV and redoSAVR in women yielded similar short‐term outcomes. Both represent valid options for treatment of degenerated aortic bioprosthesis.

Subjects

MeSH terms (MEDLINE)

BioprosthesisHeart Valve ProsthesisAortic ValveReoperationTranscatheter Aortic Valve ReplacementHeart Valve Prosthesis ImplantationProsthesis FailureAortic Valve StenosisHumansFemaleRisk FactorsTime FactorsAgedTreatment OutcomeAged, 80 and overRisk AssessmentProsthesis DesignSex FactorsRetrospective Studies

Authors and institutions

  • Department of Surgery, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, New York, USA.
  • Department of Surgery, Center for Innovation and Outcomes Research, Columbia University, New York, New York, USA.
  • Department of Medicine, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, New York, USA.

ORCID profiles: Marco Tagliafierro

Cite

APA

Tagliafierro, M., Kanade, R., Kirilina, D., Soliman, F., Anzai, I., Kodali, S., Vahl, T., Hahn, R., Nazif, T., Geirsson, A., Takayama, H., Argenziano, M., Kurlansky, P., George, I., & Pirelli, L. (2026). Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience. Catheterization and Cardiovascular Interventions, 108(2), 627-635. https://doi.org/10.1002/ccd.70693

Vancouver

Tagliafierro M, Kanade R, Kirilina D, Soliman F, Anzai I, Kodali S, et al. Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience. Catheterization and Cardiovascular Interventions. 2026;108(2):627-635. doi:10.1002/ccd.70693

BibTeX
@article{Tagliafierro2026,
  author = {Tagliafierro, Marco and Kanade, Rahul and Kirilina, Darina and Soliman, Fady and Anzai, Isao and Kodali, Susheel and Vahl, Torsten and Hahn, Rebecca and Nazif, Tamim and Geirsson, Arnar and Takayama, Hiroo and Argenziano, Michael and Kurlansky, Paul and George, Isaac and Pirelli, Luigi},
  title = {Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  volume = {108},
  number = {2},
  pages = {627--635},
  doi = {10.1002/ccd.70693}
}
Start for free →